Citius Pharmaceuticals, Inc. (CTXR) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Leonard L. Mazur	Co-Founder, Chief Executive Officer, Chairman & Secretary	712,500	1945
Jaime Bartushak	Chief Business Officer & Chief Financial Officer	589,026	1968
Myron S. Czuczman	Executive Vice President & Chief Medical Officer	607,500	1960
Myron Z. Holubiak	Co-Founder & Executive Vice Chairman	675,000	1947
Alan Lader	Senior Vice President and Head of Clinical Operations & Quality Assurance	0	N/A
Gary F. Talarico	Executive Vice President of Operations	0	1955
Dhananjay G. Wadekar	Senior Vice President of Business Strategy	0	1954
Kelly Creighton	Executive Vice President of Chemistry, Manufacturing & Controls	0	N/A
Nikolas Burlew	Executive Vice President of Quality Assurance	0	N/A
Ilanit Allen	Vice President of Investor Relations & Corporation Communications	0	N/A

Name

Title

Pay

Year Born

Leonard L. Mazur

Co-Founder, Chief Executive Officer, Chairman & Secretary

712,500

1945

Jaime Bartushak

Chief Business Officer & Chief Financial Officer

589,026

1968

Myron S. Czuczman

Executive Vice President & Chief Medical Officer

607,500

1960

Myron Z. Holubiak

Co-Founder & Executive Vice Chairman

675,000

1947

Alan Lader

Senior Vice President and Head of Clinical Operations & Quality Assurance

N/A

Gary F. Talarico

Executive Vice President of Operations

1955

Dhananjay G. Wadekar

Senior Vice President of Business Strategy

1954

Kelly Creighton

Executive Vice President of Chemistry, Manufacturing & Controls

N/A

Nikolas Burlew

Executive Vice President of Quality Assurance

N/A

Ilanit Allen

Vice President of Investor Relations & Corporation Communications

N/A

Description

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.